Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: December 21, 2022
Reporting Period: Event-specific report dated December 21, 2022.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the Company's expectation to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). This application pertains to a Phase 1b clinical trial for the Company's INTASYL compound, PH-762.
Guidance, Outlook, and Management Commentary
- Clinical Trial Outlook: The Phase 1b clinical trial for PH-762 is expected to be conducted in the United States during the first half of 2023.
- Management Commentary: The Company issued a press release on December 21, 2022, announcing the anticipated IND filing. The full text of the press release is included as Exhibit 99.1.
- Risks and Contingencies: The filing does not explicitly detail risks or contingencies beyond the inherent uncertainty of regulatory filings and clinical trial timelines.
Investor Verification Checklist
- Verify the actual submission date of the IND application for PH-762 with the FDA.
- Confirm the initiation date of the Phase 1b clinical trial in the first half of 2023.
- Review the full text of the press release (Exhibit 99.1) for additional details on the trial design and objectives.
- Monitor subsequent filings for updates on regulatory approval status or trial enrollment.